In contrast, an improvement in median survival relative to prediction could be observed across a broad range of IgM to BG-Atri for B/O patients (median OS-HPS ranging from 7.5 to 10.9 months). The gene discussed is CD40LG; the disease is Hermansky-Pudlak syndrome.